Hans‐Juergen Woerle

Author

Hans‐Juergen Woerle

Boehringer Ingelheim (Germany)

Also Known As

HANS-JUERGEN WOERLE, Hans-Juergen Woerle, Hans‐Juergen Woerle, Sanjay Patel

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United Kingdom)Boehringer Ingelheim (United States)University of Toronto Dallas Diabetes Research Center

About

Hans‐Juergen Woerle is an author at Boehringer Ingelheim (Germany) specializing in medicine, diabetes, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	964
2	Diabetes	11	11	939
3	Public Health	4	4	449
4	Health Sciences	2	2	201
5	Clinical Nutrition	1	1	23

Hans‐Juergen Woerle

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Journal of Clinical Investigation	2014	1.1K
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou, Cardiovascular Diabetology	2014	458
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Baptist Gallwitz, Julio Rosenstock, T. Rauch, The Lancet Non-pharmacological InterventionDiabetes ManagementHealth PolicyCardiovascular Disease2-Year Efficacy	2012	336
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic, Diabetes Care	2013	295
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) Bernard Zinman, Silvio E. Inzucchi, John M. Lachin, Cardiovascular Diabetology	2014	247
Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial Bruce A. Perkins, David Z.I. Cherney, Helen Partridge, Diabetes Care	2014	228
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA<sup>®</sup>) Nikolaus Marx, Julio Rosenstock, Steven E. Kahn, Diabetes and Vascular Disease Research	2015	204
Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment Janet B. McGill, Lance Alan Sloan, Jennifer Newman, Diabetes Care	2012	203
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial Christoph Wanner, Hiddo J.L. Heerspink, Bernard Zinman, Journal of the American Society of Nephrology	2018	194
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial Anthony Barnett, Holger Huisman, Russell Jones, The Lancet Metabolic SyndromeCommon Antidiabetes TreatmentsDiabetes ManagementCardiovascular DiseaseDiabetes	2013	178

Page 1